27091-83-4Relevant academic research and scientific papers
4-OXO-N-(4-HYDROXYPHENYL)RETINAMIDE DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
-
Page/Page column 11, (2016/04/10)
The present invention relates to a compound having formula (I) below or a pharmaceutically acceptable salt thereof: wherein: X is -COOH or NH2; R is a straight or branched C1-C10 alkylene chain; and R1 is H, str
NOVEL CRYSTAL FORM OF 3,4-DIFLUORO-2-(2-FLUORO-4-IODO-PHENYL AMINO)-N-(2-HYDROXY-ETHOXY)-5-(3-OXO-[1,2]OXAZINAN-2-YLMETHYL)-BENZAMIDE
-
Paragraph 0039; 0066; 0067; 0068, (2016/10/09)
PROBLEM TO BE SOLVED: To provide an active pharmaceutical ingredient that is useful as MEK inhibitors and is stable physicochemically. SOLUTION: The present invention provides an educt I-type crystal of 3,4-difluoro-2-(2-fluoro-4-iodo-phenyl amino)-n-(2-hydroxy-ethoxy)-5-(3-oxo-[1,2]oxazinan-2-ylmethyl)-benzamide, having peaks with diffraction angles expressed by 2θ of 14.9, 16.9 and 23.1° (±0.2°) in a powder X-ray diffraction pattern measured using Cu Kα(1.54060?) as an X-ray source. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT
5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR
-
Page/Page column 112-113, (2008/06/13)
An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].
On the bioisosteric potential of diazines: Diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor ridogrel
Heinisch, Gottfried,Holzer, Wolfgang,Kunz, Friedbert,Langer, Thierry,Lukavsky, Peter,Pechlaner, Christoph,Weissenberger, Hans
, p. 4058 - 4064 (2007/10/03)
In this SAR study the bioisosteric potential of diazines in the field of combined antithrombotic thromboxane A2 synthetase inhibitors and receptor antagonists was investigated. In this context, two series of (E)- and (Z)- ω-[[(aryldiazinylmethy
